Dr. Jason Luke, MD
Claim this profileUniversity of Pittsburgh Medical Center
Expert in Cancer
Expert in Solid Tumors
36 reported clinical trials
64 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Solid Tumors
Global LeaderStage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Jason Luke, MD is currently running
Immunotherapy + SBRT
for Solid Cancers
This trial tests a new treatment combining radiation, nivolumab, and BMS-986253 for patients with advanced cancers who haven't responded to other treatments. The goal is to find safe doses and see if this combination can help the immune system fight cancer more effectively. Nivolumab, often combined with ipilimumab, has shown promising results in improving survival rates in various cancers, including melanoma.
Recruiting1 award Phase 117 criteria
KFA115 + Tislelizumab
for Advanced Cancers
This trial tests a new drug, KFA115, alone and with pembrolizumab in patients with advanced cancers. It aims to find the safest dose and see if the drugs can reduce tumors. The focus is on patients whose cancers are hard to treat with current options.
Recruiting1 award Phase 18 criteria
More about Jason Luke, MD
Clinical Trial Related3 years of experience running clinical trials · Led 36 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Jason Luke, MD has experience with
- Nivolumab
- Pembrolizumab
- Atezolizumab
- Lorigerlimab
- Ipilimumab
- TAK-676
Breakdown of trials Jason Luke, MD has run
Cancer
Solid Tumors
Melanoma
- Immunotherapy + SBRT for Solid Cancers
- Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason Luke, MD specialize in?
Jason Luke, MD focuses on Cancer and Solid Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jason Luke, MD currently recruiting for clinical trials?
Yes, Jason Luke, MD is currently recruiting for 17 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Jason Luke, MD has studied deeply?
Yes, Jason Luke, MD has studied treatments such as Nivolumab, Pembrolizumab, Atezolizumab.
What is the best way to schedule an appointment with Jason Luke, MD?
Apply for one of the trials that Jason Luke, MD is conducting.
What is the office address of Jason Luke, MD?
The office of Jason Luke, MD is located at: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.